NovaBay Pharmaceuticals (NBY) 10-Q 6 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 03, 2021
Document Information [Line Items]
Entity Registrant Name	NOVABAY PHARMACEUTICALS, INC.
Entity Central Index Key	0001389545
Trading Symbol	nby
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		41,782,584
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock, par value $0.01 per share

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
ASSETS
Cash and cash equivalents	$ 10,508	$ 11,952
Accounts receivable, net of allowance for doubtful accounts ($18 and $0 at March 31, 2021 and December 31, 2020, respectively)	1,038	1,106
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($201 and $236 at March 31, 2021 and December 31, 2020, respectively)	850	608
Prepaid expenses and other current assets	750	576
Total current assets	13,146	14,242
Operating lease right-of-use assets	350	436
Property and equipment, net	100	84
Other assets	476	476
TOTAL ASSETS	14,072	15,238
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable	833	302
Accrued liabilities	1,851	2,115
Operating lease liability	396	416
Total current liabilities	3,080	2,833
Operating lease liability- non-current	9	87
Total liabilities	3,089	2,920
Stockholders' equity:
Preferred stock: 5,000 shares authorized; none issued and outstanding at March 31, 2021 and December 31, 2020
Common stock, $0.01 par value; 75,000 shares authorized, 41,782 shares issued and outstanding at March 31, 2021 and December 31, 2020	418	418
Additional paid-in capital	148,146	147,963
Accumulated deficit	(137,581)	(136,063)
Total stockholders' equity	10,983	12,318
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 14,072	$ 15,238

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Accounts receivable, allowance for doubtful accounts	$ 18	$ 0
Inventory, allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments	$ 201	$ 236
Preferred stock, shares authorized (in shares)	5,000	5,000
Preferred stock, shares outstanding (in shares)	0	0
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	75,000	75,000
Common stock, shares issued (in shares)	41,782	41,782
Common stock, shares outstanding (in shares)	41,782	41,782

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Sales:
Total sales, net	$ 1,807	$ 1,892
Product cost of goods sold	455	581
Gross profit	1,352	1,311
Operating expenses:
Research and development	5	9
Sales and marketing	1,680	1,560
General and administrative	1,187	1,277
Total operating expenses	2,872	2,846
Operating loss	(1,520)	(1,535)
Non-cash gain on changes in fair value of warrant liability		137
Non-cash gain on changes in fair value of embedded derivative liability		2
Other income (expense), net	2	(186)
Loss before provision for income taxes	(1,518)	(1,582)
Provision for income taxes
Net loss and comprehensive loss	$ (1,518)	$ (1,582)
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)	$ (0.04)	$ (0.06)
Weighted-average shares of common stock used in computing net loss per share attributable to common stockholders (basic and diluted) (in shares)	41,782	27,978
Product [Member]
Sales:
Total sales, net	$ 1,801	$ 1,892
Product and Service, Other [Member]
Sales:
Total sales, net	$ 6

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Employee [Member]Common Stock [Member]	Employee [Member]Additional Paid-in Capital [Member]	Employee [Member]AOCI Attributable to Parent [Member]	Employee [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2019					27,938
Balance at Dec. 31, 2019					$ 279	$ 125,718	$ (125,024)	$ 973
Net loss							(1,582)	(1,582)
Stock-based compensation expense related to employee and director stock options						45		45
Stock-based compensation expense related to non-employee stock options						12		12
Issuance of common stock in connection with exercise of warrants, net of issuance cost (in shares)					299
Issuance of common stock in connection with exercise of warrants, net of issuance cost					$ 3	198		201
Vesting of restricted stock awards (in shares)	2
Vesting of employee restricted stock awards		$ 2		$ 2
Balance (in shares) at Mar. 31, 2020					28,239
Balance at Mar. 31, 2020					$ 282	125,975	(126,606)	(349)
Balance (in shares) at Dec. 31, 2020					41,782
Balance at Dec. 31, 2020					$ 418	147,963	(136,063)	12,318
Net loss							(1,518)	(1,518)
Stock-based compensation expense related to employee and director stock options						130		130
Stock-based compensation expense related to non-employee stock options						53		53
Balance (in shares) at Mar. 31, 2021					41,782
Balance at Mar. 31, 2021					$ 418	$ 148,146	$ (137,581)	$ 10,983

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating activities:
Net loss	$ (1,518)	$ (1,582)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	9	14
Non-cash gain on changes in fair value of warrant liability		(137)
Non-cash gain on changes in fair value of embedded derivative liability	0	(2)
Interest expense related to amortization of debt issuance and debt discount		105
Interest expense related to amortization of debt issuance related to related party notes payable		1
Changes in operating assets and liabilities:
Accounts receivable	68	113
Inventory	(242)	(59)
Prepaid expenses and other current assets	(174)	223
Operating lease right-of-use assets	86	224
Other assets		1
Accounts payable and accrued liabilities	267	384
Operating lease liabilities	(98)	(252)
Related party notes payable		47
Long-term obligations		(4)
Net cash used in operating activities	(1,419)	(865)
Investing activities:
Purchases of property and equipment	(25)
Net cash used in investing activities	(25)
Financing activities:
Proceeds from exercise of warrants		201
Payment on the convertible note		(565)
Net cash used in financing activities		(364)
Net decrease in cash, cash equivalents, and restricted cash	(1,444)	(1,229)
Cash, cash equivalents and restricted cash, beginning of year	12,427	7,412
Cash, cash equivalents and restricted cash, end of year	10,983	6,183
Supplemental disclosure of cash flow information:
Interest paid		35
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense for options and stock issued	130	45
Nonemployees [Member] | Share-based Payment Arrangement, Option [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense for options and stock issued	53	12
Employee [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Issuance of RSUs		$ 2

Note 1 - Organization

Note 1 - Organization	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. NovaBay Pharmaceuticals, Inc. (the “Company”) is a medical device company predominantly focused on eye care. A majority of our revenue comes from Avenova®, an FDA cleared product sold in the United States that has proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from skin around the eye, including the eyelid. Avenova is formulated with our proprietary, stable and pure form of hypochlorous acid. Avenova is available directly to consumers through our online sales channel and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. We continue to promote Avenova through all four 1 2 50 3 4 2020 19 2020. Avenova was launched as an over-the-counter product during the second 2019. not The launch of over-the-counter Avenova online proved to be especially fortuitous during the COVID- 19 Over-the-counter Avenova is now our leading product by unit sales and net revenue despite having a lower average net selling price than prescription Avenova. This sales performance reflects our ongoing focus and increasing spend on digital marketing and public relations initiatives to promote Avenova directly to the end consumer. Avenova is available on Amazon.com, Walmart.com, and Avenova.com. Late in 2020, one February 2021. Although we expect the online sales channel to continue to be our fastest-growing channel, support for Avenova from the medical community is important to maintaining its reputation as a preferred product. The “doctor recommended” halo effect around our brand remains strong due in part to our continued promotion of prescription Avenova. Late in 2020, Beyond Avenova and CelleRx, we have developed additional products containing our proprietary, stable and pure form of hypochlorous acid, including NeutroPhase® and PhaseOne® for the wound care market. On March 31, 2021 In addition to our proprietary products, we responded to the national need for protective personal equipment (PPE) in the first 2020 KN95 KN95 second 2020, third fourth 2020 not not Liquidity Based primarily on the funds available at March 31, 2021, May 6, 2022. may may 19

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include contract liabilities related to product sales, useful lives for property and equipment and related depreciation calculations, assumptions for valuing options and warrants, income taxes and other contingencies. Actual results could differ from those estimates. Unaudited Interim Financial Information The accompanying unaudited interim condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not not Cash, Cash Equivalents, and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three March 31, 2021 December 31, 2020, The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets that sum to the total of the same reported in the condensed consolidated statements of cash flows (in thousands): March 31, December 31, 2021 2020 Cash and cash equivalents $ 10,508 $ 11,952 Restricted cash included in other assets 475 475 Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows $ 10,983 $ 12,427 The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord. Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a highly-rated, major financial institution in the United States. Deposits in this bank may not During the three March 31, 2021 2020, three During the three March 31, 2021 2020, Three Months Ended March 31, 2021 2020 Avenova $ 1,575 $ 1,539 KN95 Masks 8 173 NeutroPhase — 173 Other products 218 7 Total product revenue, net 1,801 1,892 Other revenue, net 6 — Total sales, net $ 1,807 $ 1,892 During the three March 31, 2021 2020, 65% 49% No 10% three March 31, 2021 2020. As of March 31, 2021 December 31, 2020, 10% March 31, December 31, Major distribution partner 2021 2020 Distributor A 19 % 14 % Amazon 19 % 11 % Distributor B 18 % 18 % Chongqing Pioneer Pharma Holdings Limited 13 % 16 % Distributor C 11 % 14 % The Company relies on two not third may may not may 19 Fair Value of Financial Assets and Liabilities The Company's financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities. The Company's cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures three may Level 1 Level 2 Level 3 Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and it believes are unlikely to be collected. At March 31, 2021, $18 December 31, 2020. Inventory Inventory is comprised of ( 1 2 3 first first March 31, 2021 December 31, 2020, $0.2 Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three seven The costs of normal maintenance, repairs, and minor replacements are expensed as incurred. Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not may The Company has elected to combine lease and non-lease components as a single component for all leases in which it is a lessee or a lessor. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. As a result, as of the effective date, the Company no Comprehensive Income (Loss) ASC 220, Comprehensive Income, Revenue Recognition Revenue generated through the Company's webstores, Avenova.com and CelleRx.com, for Avenova and CelleRx (as well as the KN95 third Revenue generated through Amazon.com and Walmart.com third The Company also generates Avenova product revenue through product sales to its major distribution partners. Product supply of Avenova is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon shipment to the distributor on a “sell-in” basis. Upon recognition of product sales, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, and product returns. The Company derives its rate of return from historical data and updates its return rate assumption quarterly. Payment for product supply is typically due 30 Revenue generated through the Company's partner pharmacies is recognized when control of the product transfers to the end customer. Revenue for product sales to CVS is recognized upon transfer of control to CVS, net of estimated future product returns. Cost of Goods Sold Cost of goods sold includes third Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities, including submissions to the Food and Drug Administration (“FDA”). Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. Advertising Costs Advertising costs are expensed in the period in which the costs are incurred. Advertising expenses were $0.7 $0.4 three March 31, 2021 2020, Stock-Based Compensation The Company's stock-based compensation includes grants of stock options and restricted stock units (“RSUs”) to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Company's condensed consolidated statements of stockholders' equity (deficit) based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes option pricing model. See Note 13, Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not Common Stock Warrant Liability The Company accounts for common stock purchase warrants issued in connection with its equity offerings in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging The Company accounts for common stock purchase warrants issued in connection with share-based compensation arrangements in accordance with the provisions of ASC 718, Stock Compensation, 480, Distinguishing Liabilities from Equity The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). Additionally, for common stock purchase warrants accounted for in accordance with ASC 718, Stock Compensation, For warrants that are classified as liabilities, the Company records the fair value of the warrants at each balance sheet date and records changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. The fair values of these warrants are determined using the Black-Scholes option pricing model, the Binomial Lattice (“Lattice”) valuation model, or the Monte Carlo simulation model where deemed appropriate. These values are subject to a significant degree of management's judgment. Net Loss Per Share The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“EPS”). Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods because their effect would be anti-dilutive. During the three March 31, 2021 2020, no The following table sets forth the calculation of basic EPS and diluted EPS (in thousands, except per share amounts): Three Months Ended March 31, Numerator 2021 2020 Net loss $ (1,518 ) $ (1,582 ) Denominator Weighted average shares of common stock outstanding, basic and diluted 41,782 27,978 Net loss per share attributable to common stockholders, basic and diluted $ (0.04 ) $ (0.06 ) The following outstanding stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive (in thousands): As of March 31, 2021 2020 Stock options 3,138 2,099 Stock warrants 7,082 8,247 10,220 10,346 Recent Accounting Pronouncements In June 2016, 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13” 2016 13 2016 13 January 1, 2023. January 1, 2023. In December 2019, 2019 12, Income Taxes (Topic 740 Simplifying the Accounting for Income Taxes January 1, 2021, not In August 2020, 2020 06, Debt Debt with Conversion and Other Options (Subtopic 470 20 Contracts in Entity s Own Equity (Subtopic 815 40 s Own Equity 2020 06” . 2020 06 1 2 2020 06 no December 15, 2021, no December 15, 2020. 2020 06 first 2023. 2020 06

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3. The Company follows ASC 820, Fair Value Measurements and Disclosures The Company's cash equivalents are classified within Level 1 1 The following table presents the Company's assets measured at fair value on a recurring basis as of March 31, 2021( Fair Value Measurements Using Balance at March 31, 2021 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 151 151 — — Total assets $ 475 $ 475 $ — $ — The following table presents the Company's assets measured at fair value on a recurring basis as of December 31, 2020 ( Fair Value Measurements Using Balance at December 31, 2020 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 151 151 — — Total assets $ 475 $ 475 $ — $ — There were no March 31, 2021 December 31, 2020.

Note 4 - Prepaid Expenses and O

Note 4 - Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Prepaid Expenses and Other Current Assets [Text Block]	NOTE 4. Prepaid expenses and other current assets consisted of the following (in thousands): March 31, December 31, 2021 2020 Insurance claim receivable $ 321 $ — Prepaid insurance 77 165 Prepaid sales rebates 68 144 Prepaid inventory 68 — Prepaid security deposit for lease — 65 Prepaid dues and subscription 54 53 Prepaid patents 31 47 Other 131 102 Total prepaid expenses and other current assets $ 750 $ 576

Note 5 - Inventory

Note 5 - Inventory	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 5. Inventory consisted of the following (in thousands): March 31, December 31, 2021 2020 Raw materials and supplies $ 193 $ 159 Finished goods 858 685 Less: Reserve for excess and obsolete inventory (201 ) (236 ) Total inventory, net $ 850 $ 608

Note 6 - Property and Equipment

Note 6 - Property and Equipment	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 6. Property and equipment consisted of the following (in thousands): March 31, December 31, 2021 2020 Office and laboratory equipment $ 20 $ 20 Furniture and fixtures 157 157 Computer equipment and software 390 365 Production equipment 65 65 Leasehold improvements 79 79 Total property and equipment, at cost 711 686 Less: accumulated depreciation and amortization (611 ) (602 ) Total property and equipment, net $ 100 $ 84 Depreciation and amortization expense was $9 $14 three March 31, 2021 2020,

Note 7 - Accrued Liabilities

Note 7 - Accrued Liabilities	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 7. Accrued liabilities consisted of the following (in thousands): March 31, December 31, 2021 2020 Avenova contract liabilities $ 862 $ 730 Employee payroll and benefits 265 632 Sublease security deposit 175 198 Consulting services 153 98 Audit services 122 — Inventory purchases — 181 Other 274 276 Total accrued liabilities $ 1,851 $ 2,115

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 8. Directors and Officers Indemnification As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company's request in such capacity. The term of the indemnification period is for the officer's or director's lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may not March 31, 2021. In the normal course of business, the Company provides indemnification of varying scope under its agreements with other companies, typically its clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with the use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third not March 31, 2021. Legal Matters On July 29, 2019, December 2020. During the first 2021, $0.3 March 31, 2021 ( 4, As of March 31, 2021, no Leases The Company leases office space for its corporate headquarters located in Emeryville, California. The initial lease term is through February 28, 2022. one five 5 The Company also had a lease commitment for laboratory facilities and office space at EmeryStation North in Emeryville, California (“EmeryStation”) under an operating lease. In July 2016, September 8, 2016. August 31, 2020 July 31, 2020. The components of lease expense for the three March 31, 2021 2020 Lease Costs Three Months Ended March 31, 2021 2020 Operating lease cost $ 99 $ 264 Sublease income — (158 ) Net lease cost $ 99 $ 106 Other information Operational cash flow used for operating leases $ 113 $ 296 The Company has measured its operating lease liabilities at its incremental borrowing rate over the remaining term for each operating lease. The weighted average remaining lease term and the weighted average discount rate are summarized as follows: Three Months Ended March 31, 2021 2020 Weighted-average remaining lease term (in years) 1.0 1.5 Weighted-average discount rate 12 % 12 % Future lease payments under non-cancelable leases as of March 31, 2021 2021 $ 341 2022 88 Thereafter — Total future minimum lease payments 429 Less imputed interest (24 ) Total $ 405 Reported as: Operating lease liability $ 396 Operating lease liability- non-current 9 Total $ 405 Contracts On May 13, 2020, September 4, 2020 February 4, 2021. 15,000 $0.6718 January 15, 2021. On April 16, 2020, 2 12% December 31, 2021. March 31, 2021, not In connection with the Microprofit Agreement, on April 16, 2020, June 29, 2020.

Note 9 - Related Party Note Pay

Note 9 - Related Party Note Payable	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Related Party Notes Payable [Text Block]	NOTE 9. PAYABLE On February 27, 2019, $1.0 June 25, 2019 May 14, 2020 ( $0.2 $0.3 65,178 40ml second May 14, 2020, $1.0 12, two 2020. December 31, 2020, In connection with the Promissory Note, the Company 2% one March 1, 2020. $0.1 no $20 The interest expense recognized, including amortization of the issuance costs, was $48 three March 31, 2020. no three March 31, 2021.

Note 10 - Convertible Note

Note 10 - Convertible Note	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 10. On March 26, 2019, March 26, 2019. $2.2 10% September 26, 2020, $2.0 $0.2 $15 $0.2 third 2020. During the three March 31, 2020, $2 no three March 31, 2021. During the three March 31, 2020, 54% $0.1 no three March 31, 2021.

Note 11 - Warrant Liability

Note 11 - Warrant Liability	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	NOTE 11. July 2011 The Company issued the July 2011 12, third 2011. July 2011 480, Distinguishing Liabilities from Equity July 2011 On March 6, 2020, 35,107 July 2011 no July 2011 March 31, 2021. October 2015 The Company issued the October 2015 12, third 2015. October 2015 480, Distinguishing Liabilities from Equity October 2015 During the fourth 2020, 22,680 October 2015 $5 $12 On October 27, 2020, 15,320 October 2015 no October 2015 March 31, 2021. 2019 As further described in Note 12, 2019 2019 2019 third 2019. 2019 2019 2019 480, Distinguishing Liabilities from Equity Upon issuance, the fair value of the 2019 2019 2019 $3.1 $2.0 $0.1 In the third 2020, 12, 2019 2019 2019 2019 $4.9 $4.2 Assumptions 2019 Domestic Warrants 2019 Foreign Warrants Expected price volatility 178 % 178 % Expected term (in years) 4.57 4.57 Risk-free interest rate 0.25 % 0.27 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrant $ 1.18 $ 1.54 There were no 2019 2019 March 31, 2021. In the third 2020, 12, 2019 2019 no 2019 $0.2 Expected price volatility 186 % Expected term (in years) 4.05 Risk-free interest rate 0.22 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 1.17 The 2019 no 2019 March 31, 2021.

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 12. EQUITY Preferred Stock The Company is authorized to issue up to 5,000,000 may no March 31, 2021 December 31, 2020. Common Stock April 2020 In the second 2020, 8 April 27, 2020 June 15, 2020. second 2020, 5,836,792 $5.6 $0.4 TLF Bio Innovation Stock Purchase On May 13, 2020, 1,000 $1 8, Common Stock Warrants July 2011 In the third 2011, 139,520 139,520 “July 2011 July 2011 $33.25 July 5, 2016. October 2015, July 2011 $5.00 March 6, 2020. February 2016 May 2019, July 2011 $1.81 $0.2061 In March 2020, 35,107 July 2011 March 31, 2021, no July 2011 March 2015 In the first 2015, 649,133 649,133 “March 2015 March 2015 $15.00 $16.25 278,200 March 2015 March 6, 2020 370,933 March 2015 June 6, 2015. October 2015, March 2015 $5.00 June 6, 2015 March 6, 2020. February 2016 May 2019, July 2011 $1.81 $0.2061 During the first 2020, 70,000 March 2015 $14 In the first 2020, 7,419 March 2015 March 31, 2021, no March 2015 October 2015 In the fourth 2015, 442,802 442,802 “October 2015 $5.00 October 27, 2020. February 2016 May 2019, October 2015 $1.81 $0.2061 During the fourth 2020, 22,680 October 2015 $5 During the fourth 2020, 15,320 October 2015 March 31, 2021, no October 2015 June 2019 June 2019 During the second 2019, 1,371,427 1,371,427 1,371,427 “June 2019 $2.4 $1.0 $0.4 $1.0 six 6% $0.1 $27 The June 2019 $0.87 June 17, 2020. June 2019 $1.00 During the first 2020, 228,571 June 2019 $199 $12 six 6% During the second 2020, 571,428 June 2019 $497 $29 six 6% During the second 2020, 571,428 June 2019 March 31, 2021, no June 2019 August 2019 2019 2019 2019 In the third 2019, 4,198,566 4,198,566 4,198,566 “2019 $4.2 2019 $1.15 February 13, 2025. The Company allocated the proceeds between the common stock and 2019 first $3.1 2019 11, 2019 Ladenburg served as the placement agent for the transaction in exchange for a commission representing six 6% $0.3 167,942 167,942 $1.25 August 8, 2024 ( “2019 $60 $0.3 The Company incurred total issuance costs of $0.5 $0.2 $0.3 2019 $59 $65 11, 2019 During the third 2020, 2019 2019 $0.99. $6.8 $0.2 $0.2 six 6% 2019 During the third 2020, 2019 2019 2019 2019 1 2019 2019 $0.99 2 100% 2019 2019 The New Warrants became exercisable six 6,898,566 $1.65 five 2019 2019 one not During the third 2020, $0.99 2019 11, 2019 no TLF Bio Innovation 2021 On January 15, 2021, 15,000 $0.6718 five The details of all outstanding warrants as of March 31, 2021 Warrants (in thousands) Weighted- Average Exercise Price Outstanding at December 31, 2020 7,067 $ 1.63 Warrants granted 15 $ 0.67 Warrants exercised — $ — Warrants expired — $ — Outstanding at March 31, 2021 7,082 $ 1.63

Note 13 - Equity-based Compensa

Note 13 - Equity-based Compensation	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	NOTE 13. Equity Compensation Plans In October 2007, 2007 “2007 2007 March 15, 2017. 2007 2007 no ten 2007 December 31, 2020. In March 2017, 2017 “2017 June 2, 2017, 2017 not 2007 2017 2,318,486 first January 1, 2018 January 1, 2027 4% 4 2017 January 15, 2021, 2017 1,671,303 March 31, 2021, 3,646,727 2017 Under the terms of the 2017 may not 100% 10% not 110% not ten not five 10% four 2007 2017 Stock Option Summary The following table summarizes information about the Company's stock options and restricted stock outstanding at March 31, 2021 March 31, 2021: (in thousands, except years and per share data) Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2020 3,165 $ 2.05 7.6 $ 189 Options granted 55 $ 1.09 Restricted stock units granted - $ — Options exercised - $ — Restricted stock units vested - $ — Options forfeited/cancelled (82 ) $ 3.97 Restricted stock units cancelled - $ — Outstanding at March 31, 2021 3,138 $ 1.98 7.4 $ 309 Vested and expected to vest at March 31, 2021 2,797 $ 2.12 7.2 $ 254 Vested at March 31, 2021 1,459 $ 3.21 5.3 $ 64 Exercisable at March 31, 2021 1,459 $ 3.21 5.3 $ 64 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company's common stock as quoted on the NYSE American as of March 31, 2021 no three March 31, 2021 2020. no three March 31, 2021 2020. As of March 31, 2021, $0.9 2.62 Stock Option Awards to Employees and Directors The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2, During the three March 31, 2021 2020, 55,000 20,000 The weighted-average assumptions used in determining the value of options are as follows: Three Months Ended March 31, Assumption 2021 2020 Expected price volatility 164.44 % 143.83 % Expected term (in years) 6.19 6.46 Risk-free interest rate 1.09 % 0.99 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 1.04 $ 0.53 Expected Price Volatility Expected Term Risk-Free Interest Rate Dividend Yield not Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. In addition, during the three March 31, 2021 2020, not For the three March 31, 2021 2020, $130 $45 Stock-Based Awards to Non-Employees During the three March 31, 2021 March 31, 2020, not When the Company grants stock options, the stock options are recorded at their fair value on the grant date and recognized over the respective service or vesting period. The fair value of the stock options that are granted is calculated using the Black-Scholes-Merton option pricing model as discussed above. In addition, during the three March 31, 2021 2020, not For the three March 31, 2021 2020, $53 $12 Summary of Stock-Based Compensation Expense A summary of the stock-based compensation expense included in results of operations for the options and restricted stock awards discussed above is as follows (in thousands): Three Months Ended March 31, 2021 2020 Research and development $ 4 $ 7 Sales and marketing 31 9 General and administrative 148 41 Total stock-based compensation expense $ 183 $ 57

Note 14 - License, Collaboratio

Note 14 - License, Collaboration and Distribution Agreements	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
License, Collaboration, and Distribution Agreements [Text Block]	NOTE 14. Transactions under the Company's major distribution agreements are recognized upon transfer of control of product sold to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the amounts that are estimated to be subject to significant reversal, including allowances for services, discounts, rebate programs, and product returns. The following table presents changes in the Company's contract assets and liabilities for the three March 31, 2021 ( Balance at Additions Deductions Balance at Contract Liabilities: Deferred Revenue $ 2 $ 1 $ (2 ) $ 1 Contract Liabilities: Accrued Liabilities 573 573 (352 ) 794 Total $ 575 $ 574 $ (354 ) $ 795 During the three March 31, 2021 2020, Three Months Ended March 31, 2021 2020 Revenue recognized in the period from: Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 575 $ 434 New activities in the period: Performance obligations satisfied 1,232 1,458 $ 1,807 $ 1,892 Avenova Distribution Agreements and Specialty Pharmacies Prescription Avenova is made available in local pharmacies and major pharmacy retail chains under nationwide distribution agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. We have also entered into direct agreements with preferred pharmacy networks as part of our Partner Pharmacy Program. During the three March 31, 2021 2020, $0.1 $0.6 Under the prescription Avenova product distribution arrangements, the Company had a contract liability balance of $0.9 $0.7 March 31, 2021 December 31, 2020, $68 $0.1 March 31, 2021 December 31, 2020, 4, Over-the-counter Avenova Non-prescription Avenova was launched online on June 1, 2019 three March 31, 2021 2020, $1.2 $0.8

Note 15 - Employee Benefit Plan

Note 15 - Employee Benefit Plan	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Retirement Benefits [Text Block]	NOTE 15. The Company has a 401 not no three March 31, 2021 2020.

Note 16 - Related Party Transac

Note 16 - Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 16. Related Party Revenue The following table summarizes information about the Company's related party revenue and cost of goods sold during the three March 31, 2021 2020, Three Months Ended March 31, 2021 2020 Related party revenue: NeutroPhase $ — $ 173 Total related party revenue $ — $ 173 Cost of goods sold NeutroPhase $ — $ 90 Total related party expenses $ — $ 90 Related party accounts receivable was $0.1 $0.2 March 31, 2021 December 31, 2020, Other Related Party Expenses During the three March 31, 2021 December 31, 2020, KN95 March 31, 2021 December 31, 2020, $10 $8 The following table summarizes information about the Company's other related party expenses excluding stock-based compensation during the three March 31, 2021 2020, Three Months Ended March 31, 2021 2020 Commissions to China Kington related to: Exercise of June 2019 Warrants $ — $ 12 Total commissions to China Kington — 12 Board Director Bob Wu consulting fee — 50 Total related party expenses $ — $ 62 In connection with the Company's re-launch of CelleRx Clinical Reset, on November 17, 2020, twelve 300,000 2017 one $30 three March 31, 2021

Note 17 - Paycheck Protection P

Note 17 - Paycheck Protection Program	3 Months Ended
	Mar. 31, 2021
COVID 19 Member [Member]
Notes to Financial Statements
Unusual or Infrequent Items, or Both, Disclosure [Text Block]	NOTE 17. On May 6, 2020, $0.9 March 27, 2020.The 2020, June 5, 2020. 1.00% two 2021. may no may 24

Note 18 - Subsequent Events

Note 18 - Subsequent Events	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 18. The disclosure set forth in Part II, Item 5

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include contract liabilities related to product sales, useful lives for property and equipment and related depreciation calculations, assumptions for valuing options and warrants, income taxes and other contingencies. Actual results could differ from those estimates.
Unaudited Interim Financial Information, Policy [Policy Text Block]	Unaudited Interim Financial Information The accompanying unaudited interim condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents, and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three March 31, 2021 December 31, 2020, The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets that sum to the total of the same reported in the condensed consolidated statements of cash flows (in thousands): March 31, December 31, 2021 2020 Cash and cash equivalents $ 10,508 $ 11,952 Restricted cash included in other assets 475 475 Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows $ 10,983 $ 12,427 The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a highly-rated, major financial institution in the United States. Deposits in this bank may not During the three March 31, 2021 2020, three During the three March 31, 2021 2020, Three Months Ended March 31, 2021 2020 Avenova $ 1,575 $ 1,539 KN95 Masks 8 173 NeutroPhase — 173 Other products 218 7 Total product revenue, net 1,801 1,892 Other revenue, net 6 — Total sales, net $ 1,807 $ 1,892 During the three March 31, 2021 2020, 65% 49% No 10% three March 31, 2021 2020. As of March 31, 2021 December 31, 2020, 10% March 31, December 31, Major distribution partner 2021 2020 Distributor A 19 % 14 % Amazon 19 % 11 % Distributor B 18 % 18 % Chongqing Pioneer Pharma Holdings Limited 13 % 16 % Distributor C 11 % 14 % The Company relies on two not third may may not may 19
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Assets and Liabilities The Company's financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities. The Company's cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures three may Level 1 Level 2 Level 3 Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and it believes are unlikely to be collected. At March 31, 2021, $18 December 31, 2020.
Inventory, Policy [Policy Text Block]	Inventory Inventory is comprised of ( 1 2 3 first first March 31, 2021 December 31, 2020, $0.2
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three seven The costs of normal maintenance, repairs, and minor replacements are expensed as incurred.
Lessee, Leases [Policy Text Block]	Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not may The Company has elected to combine lease and non-lease components as a single component for all leases in which it is a lessee or a lessor. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. As a result, as of the effective date, the Company no
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) ASC 220, Comprehensive Income,
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Revenue generated through the Company's webstores, Avenova.com and CelleRx.com, for Avenova and CelleRx (as well as the KN95 third Revenue generated through Amazon.com and Walmart.com third The Company also generates Avenova product revenue through product sales to its major distribution partners. Product supply of Avenova is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon shipment to the distributor on a “sell-in” basis. Upon recognition of product sales, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, and product returns. The Company derives its rate of return from historical data and updates its return rate assumption quarterly. Payment for product supply is typically due 30 Revenue generated through the Company's partner pharmacies is recognized when control of the product transfers to the end customer. Revenue for product sales to CVS is recognized upon transfer of control to CVS, net of estimated future product returns.
Cost of Goods Sold, Policy [Policy Text Block]	Cost of Goods Sold Cost of goods sold includes third
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities, including submissions to the Food and Drug Administration (“FDA”).
Patent Costs Policy [Policy Text Block]	Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.
Advertising Cost [Policy Text Block]	Advertising Costs Advertising costs are expensed in the period in which the costs are incurred. Advertising expenses were $0.6 $0.4 three March 31, 2021 2020,
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company's stock-based compensation includes grants of stock options and restricted stock units (“RSUs”) to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Company's condensed consolidated statements of stockholders' equity (deficit) based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes option pricing model. See Note 13,
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not
Warrant Liabilities [Policy Text Block]	Common Stock Warrant Liability The Company accounts for common stock purchase warrants issued in connection with its equity offerings in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging The Company accounts for common stock purchase warrants issued in connection with share-based compensation arrangements in accordance with the provisions of ASC 718, Stock Compensation, 480, Distinguishing Liabilities from Equity The Company classifies as equity any contracts that (i) require physical settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside the control of the Company) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). Additionally, for common stock purchase warrants accounted for in accordance with ASC 718, Stock Compensation, For warrants that are classified as liabilities, the Company records the fair value of the warrants at each balance sheet date and records changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations and comprehensive loss. The fair values of these warrants are determined using the Black-Scholes option pricing model, the Binomial Lattice (“Lattice”) valuation model, or the Monte Carlo simulation model where deemed appropriate. These values are subject to a significant degree of management's judgment.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“EPS”). Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods because their effect would be anti-dilutive. During the three March 31, 2021 2020, no The following table sets forth the calculation of basic EPS and diluted EPS (in thousands, except per share amounts): Three Months Ended March 31, Numerator 2021 2020 Net loss $ (1,518 ) $ (1,582 ) Denominator Weighted average shares of common stock outstanding, basic and diluted 41,782 27,978 Net loss per share attributable to common stockholders, basic and diluted $ (0.04 ) $ (0.06 ) The following outstanding stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive (in thousands): As of March 31, 2021 2020 Stock options 3,138 2,099 Stock warrants 7,082 8,247 10,220 10,346
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In June 2016, 2016 13, Financial Instruments Credit Losses (Topic 326 2016 13” 2016 13 2016 13 January 1, 2023. January 1, 2023. In December 2019, 2019 12, Income Taxes (Topic 740 Simplifying the Accounting for Income Taxes January 1, 2021, not In August 2020, 2020 06, Debt Debt with Conversion and Other Options (Subtopic 470 20 Contracts in Entity s Own Equity (Subtopic 815 40 s Own Equity 2020 06” . 2020 06 1 2 2020 06 no December 15, 2021, no December 15, 2020. 2020 06 first 2023. 2020 06

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]	March 31, December 31, 2021 2020 Cash and cash equivalents $ 10,508 $ 11,952 Restricted cash included in other assets 475 475 Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows $ 10,983 $ 12,427
Schedules of Concentration of Risk, by Product [Table Text Block]	Three Months Ended March 31, 2021 2020 Avenova $ 1,575 $ 1,539 KN95 Masks 8 173 NeutroPhase — 173 Other products 218 7 Total product revenue, net 1,801 1,892 Other revenue, net 6 — Total sales, net $ 1,807 $ 1,892
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	March 31, December 31, Major distribution partner 2021 2020 Distributor A 19 % 14 % Amazon 19 % 11 % Distributor B 18 % 18 % Chongqing Pioneer Pharma Holdings Limited 13 % 16 % Distributor C 11 % 14 %
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, Numerator 2021 2020 Net loss $ (1,518 ) $ (1,582 ) Denominator Weighted average shares of common stock outstanding, basic and diluted 41,782 27,978 Net loss per share attributable to common stockholders, basic and diluted $ (0.04 ) $ (0.06 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of March 31, 2021 2020 Stock options 3,138 2,099 Stock warrants 7,082 8,247 10,220 10,346

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements Using Balance at March 31, 2021 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 151 151 — — Total assets $ 475 $ 475 $ — $ — Fair Value Measurements Using Balance at December 31, 2020 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 151 151 — — Total assets $ 475 $ 475 $ — $ —

Note 4 - Prepaid Expenses and_2

Note 4 - Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	March 31, December 31, 2021 2020 Insurance claim receivable $ 321 $ — Prepaid insurance 77 165 Prepaid sales rebates 68 144 Prepaid inventory 68 — Prepaid security deposit for lease — 65 Prepaid dues and subscription 54 53 Prepaid patents 31 47 Other 131 102 Total prepaid expenses and other current assets $ 750 $ 576

Note 5 - Inventory (Tables)

Note 5 - Inventory (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, December 31, 2021 2020 Raw materials and supplies $ 193 $ 159 Finished goods 858 685 Less: Reserve for excess and obsolete inventory (201 ) (236 ) Total inventory, net $ 850 $ 608

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, December 31, 2021 2020 Office and laboratory equipment $ 20 $ 20 Furniture and fixtures 157 157 Computer equipment and software 390 365 Production equipment 65 65 Leasehold improvements 79 79 Total property and equipment, at cost 711 686 Less: accumulated depreciation and amortization (611 ) (602 ) Total property and equipment, net $ 100 $ 84

Note 7 - Accrued Liabilities (T

Note 7 - Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, December 31, 2021 2020 Avenova contract liabilities $ 862 $ 730 Employee payroll and benefits 265 632 Sublease security deposit 175 198 Consulting services 153 98 Audit services 122 — Inventory purchases — 181 Other 274 276 Total accrued liabilities $ 1,851 $ 2,115

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Lease, Cost [Table Text Block]	Lease Costs Three Months Ended March 31, 2021 2020 Operating lease cost $ 99 $ 264 Sublease income — (158 ) Net lease cost $ 99 $ 106 Other information Operational cash flow used for operating leases $ 113 $ 296 Three Months Ended March 31, 2021 2020 Weighted-average remaining lease term (in years) 1.0 1.5 Weighted-average discount rate 12 % 12 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2021 $ 341 2022 88 Thereafter — Total future minimum lease payments 429 Less imputed interest (24 ) Total $ 405 Reported as: Operating lease liability $ 396 Operating lease liability- non-current 9 Total $ 405

Note 11 - Warrant Liability (Ta

Note 11 - Warrant Liability (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Derivative Instruments [Table Text Block]	Assumptions 2019 Domestic Warrants 2019 Foreign Warrants Expected price volatility 178 % 178 % Expected term (in years) 4.57 4.57 Risk-free interest rate 0.25 % 0.27 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrant $ 1.18 $ 1.54 Expected price volatility 186 % Expected term (in years) 4.05 Risk-free interest rate 0.22 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 1.17

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants (in thousands) Weighted- Average Exercise Price Outstanding at December 31, 2020 7,067 $ 1.63 Warrants granted 15 $ 0.67 Warrants exercised — $ — Warrants expired — $ — Outstanding at March 31, 2021 7,082 $ 1.63

Note 13 - Equity-based Compen_2

Note 13 - Equity-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	(in thousands, except years and per share data) Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2020 3,165 $ 2.05 7.6 $ 189 Options granted 55 $ 1.09 Restricted stock units granted - $ — Options exercised - $ — Restricted stock units vested - $ — Options forfeited/cancelled (82 ) $ 3.97 Restricted stock units cancelled - $ — Outstanding at March 31, 2021 3,138 $ 1.98 7.4 $ 309 Vested and expected to vest at March 31, 2021 2,797 $ 2.12 7.2 $ 254 Vested at March 31, 2021 1,459 $ 3.21 5.3 $ 64 Exercisable at March 31, 2021 1,459 $ 3.21 5.3 $ 64
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2021 2020 Research and development $ 4 $ 7 Sales and marketing 31 9 General and administrative 148 41 Total stock-based compensation expense $ 183 $ 57
Employees and Directors [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended March 31, Assumption 2021 2020 Expected price volatility 164.44 % 143.83 % Expected term (in years) 6.19 6.46 Risk-free interest rate 1.09 % 0.99 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 1.04 $ 0.53

Note 14 - License, Collaborat_2

Note 14 - License, Collaboration and Distribution Agreements (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Balance at Additions Deductions Balance at Contract Liabilities: Deferred Revenue $ 2 $ 1 $ (2 ) $ 1 Contract Liabilities: Accrued Liabilities 573 573 (352 ) 794 Total $ 575 $ 574 $ (354 ) $ 795
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2021 2020 Revenue recognized in the period from: Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 575 $ 434 New activities in the period: Performance obligations satisfied 1,232 1,458 $ 1,807 $ 1,892

Note 16 - Related Party Trans_2

Note 16 - Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	Three Months Ended March 31, 2021 2020 Related party revenue: NeutroPhase $ — $ 173 Total related party revenue $ — $ 173 Cost of goods sold NeutroPhase $ — $ 90 Total related party expenses $ — $ 90 Three Months Ended March 31, 2021 2020 Commissions to China Kington related to: Exercise of June 2019 Warrants $ — $ 12 Total commissions to China Kington — 12 Board Director Bob Wu consulting fee — 50 Total related party expenses $ — $ 62

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Accounts Receivable, Allowance for Credit Loss, Ending Balance	$ 18
Inventory Valuation Reserves, Ending Balance	201		$ 236
Increase in Accrual for Future Returns	$ 700	$ 400
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Computer Equipment and Software [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Revenue from Contract with Customer Benchmark [Member] | Distributor Concentration Risk [Member] | Avenova Product [Member]
Concentration Risk, Percentage	65.00%	49.00%

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Cash and cash equivalents	$ 10,508	$ 11,952
Restricted cash included in other assets	475	475
Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows	$ 10,983	$ 12,427	$ 6,183	$ 7,412

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Total sales, net	$ 1,807	$ 1,892
Avenova Product [Member]
Total sales, net	1,575	1,539
KN95 Masks [Member]
Total sales, net	8	173
NeutroPhase [Member]
Total sales, net		173
Other Products [member]
Total sales, net	218	7
Total Product Revenue [Member]
Total sales, net	1,801	1,892
Product and Service, Other [Member]
Total sales, net	$ 6

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable From Major Distribution Partners and Customers (Details) - Customer Concentration Risk [Member] - Accounts Receivable [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Distributor A [Member]
Distribution or collaboration partners	19.00%	14.00%
Avenova Direct [Member]
Distribution or collaboration partners	19.00%	11.00%
Distributor B [Member]
Distribution or collaboration partners	18.00%	18.00%
Chongqing Pioneer Pharma Holdings Limited [Member]
Distribution or collaboration partners	13.00%	16.00%
Distributor C [Member]
Distribution or collaboration partners	11.00%	14.00%

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Calculation of Basic and Diluted EPS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net loss	$ (1,518)	$ (1,582)
Weighted average shares of common stock outstanding, basic and diluted (in shares)	41,782	27,978
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.04)	$ (0.06)

Note 2 - Summary of Significa_8

Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded From the Diluted Net Loss Per Share Computation (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Anti-dilutive securities (in shares)	10,220	10,346
Share-based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)	3,138	2,099
Warrant [Member]
Anti-dilutive securities (in shares)	7,082	8,247

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Restricted cash held as a certificate of deposit	$ 324	$ 324
Deposit held as a certificate of deposit	151	151
Total assets	475	475
Fair Value, Inputs, Level 1 [Member]
Restricted cash held as a certificate of deposit	324	324
Deposit held as a certificate of deposit	151	151
Total assets	475	475
Fair Value, Inputs, Level 2 [Member]
Restricted cash held as a certificate of deposit
Deposit held as a certificate of deposit
Total assets
Fair Value, Inputs, Level 3 [Member]
Restricted cash held as a certificate of deposit
Deposit held as a certificate of deposit
Total assets

Note 4 - Prepaid Expenses and_3

Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Insurance claim receivable	$ 321
Prepaid insurance	77	165
Prepaid sales rebates	68	144
Prepaid inventory	68
Prepaid security deposit for lease		65
Prepaid dues and subscription	54	53
Prepaid patents	31	47
Other	131	102
Total prepaid expenses and other current assets	$ 750	$ 576

Note 5 - Inventory - Summary of

Note 5 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Raw materials and supplies	$ 193	$ 159
Finished goods	858	685
Less: Reserve for excess and obsolete inventory	(201)	(236)
Total inventory, net	$ 850	$ 608

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Depreciation, Depletion and Amortization, Total	$ 9	$ 14

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Property and equipment, at cost	$ 711	$ 686
Less: accumulated depreciation and amortization	(611)	(602)
Total property and equipment, net	100	84
Equipment [Member]
Property and equipment, at cost	20	20
Furniture and Fixtures [Member]
Property and equipment, at cost	157	157
Computer Equipment and Software [Member]
Property and equipment, at cost	390	365
Production Equipment [Member]
Property and equipment, at cost	65	65
Leasehold Improvements [Member]
Property and equipment, at cost	$ 79	$ 79

Note 7 - Accrued Liabilities -

Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Avenova contract liabilities	$ 862	$ 730
Employee payroll and benefits	265	632
Sublease security deposit	175	198
Consulting services	153	98
Audit services	122
Inventory purchases		181
Other	274	276
Total accrued liabilities	$ 1,851	$ 2,115

Note 8 - Commitments and Cont_3

Note 8 - Commitments and Contingencies (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Mar. 31, 2021	Jan. 15, 2021	Dec. 31, 2020	Apr. 16, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.63		$ 1.63
TLF Bio Innovation 2021 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		15,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.6718
Warrants in Connection with Microprofit Agreement [Member]
Class of Warrant or Right, Number of Securities Callable by Warrants or Rights Represented as Percentage of Company’s Outstanding Common Stock				12.00%
KBSIII Towers [Member]
Lessee, Operating Lease, Renewal Term (Year)	5 years
Prepaid Expenses and Other Current Assets [Member]
Insurance Reimbursement	$ 0.3

Note 8 - Commitments and Cont_4

Note 8 - Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating lease cost	$ 99	$ 264
Sublease income		(158)
Net lease cost	99	106
Operational cash flow used for operating leases	$ 113	$ 296
Weighted-average remaining lease term (in years) (Year)	1 year	1 year 182 days
Weighted-average discount rate	12.00%	12.00%

Note 8 - Commitments and Cont_5

Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
2021	$ 341
2022	88
Thereafter
Total future minimum lease payments	429
Less imputed interest	(24)
Total	405
Operating lease liability	396	$ 416
Operating lease liability- non-current	9	$ 87
Total	$ 405

Note 9 - Related Party Note P_2

Note 9 - Related Party Note Payable (Details Textual) - USD ($) $ in Thousands	May 14, 2020	Feb. 27, 2019	Mar. 31, 2021	Mar. 31, 2020
Pioneer Hong Kong [Member] | Promissory Note [Member]
Debt Instrument, Face Amount		$ 1,000
Debt Instrument, Periodic Payment, Interest	$ 300	200
Repayments of Long-term Debt, Total	$ 1,000
Debt Issuance Costs, Net, Total		$ 20
Interest Expense, Total			$ 0	$ 48
China Kington [Member]
Brokering Fee, Percent		2.00%
Consulting Agreement, Term (Year)		1 year
Consulting Agreement, Amount		$ 100

Note 10 - Convertible Note (Det

Note 10 - Convertible Note (Details Textual) - USD ($) $ in Thousands	Mar. 26, 2019	Mar. 31, 2021	Mar. 31, 2020
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net, Total		$ 0	$ 2
Iliad Research and Trading, L.P. [Member] | Secured Convertible Promissory Note [member]
Debt Instrument, Face Amount	$ 2,200
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Proceeds from Convertible Debt	$ 2,000
Debt Instrument, Original Issue Discount	200
Debt Instrument, Fee Amount	15
Deferred Finance Costs Excluding Transaction Fees	$ 200
Debt Instrument, Interest Rate During Period			54.00%
Interest Expense, Debt, Total		$ 0	$ 100

Note 11 - Warrant Liability (De

Note 11 - Warrant Liability (Details Textual) - USD ($) $ in Thousands	Oct. 27, 2020	Mar. 06, 2020	Mar. 31, 2020	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Aug. 13, 2019
Class of Warrant or Right, Outstanding (in shares)				7,082,000	7,067,000
Class of Warrant or Right, Exercised During Period (in shares)
Proceeds from Warrant Exercises						$ 6,800	$ 201
The July 2011 Warrants [Member]
Class of Warrant or Right, Expired During Period (in shares)		35,107	35,107
Class of Warrant or Right, Outstanding (in shares)				0
October 2015 Warrants [Member]
Class of Warrant or Right, Expired During Period (in shares)	15,320				15,320
Class of Warrant or Right, Outstanding (in shares)				0	0
Class of Warrant or Right, Exercised During Period (in shares)					22,680
Proceeds from Warrant Exercises					$ 5
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity					$ 12
The 2019 Domestic Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)				0
Warrants and Rights Outstanding						4,900		$ 3,100	$ 3,100
The 2019 Foreign Warrants [Member]
Warrants and Rights Outstanding						4,200			2,000
The 2019 Ladenburg Warrants [Member]
Warrants and Rights Outstanding						$ 200			$ 100

Note 11 - Warrant Liability - T

Note 11 - Warrant Liability - The Key Assumptions Used to Value the Warrants (Details)	Dec. 31, 2019
Measurement Input, Price Volatility [Member] | The 2019 Domestic Warrants [Member]
Warrants assumptions	1.78
Measurement Input, Price Volatility [Member] | The 2019 Foreign Warrants [Member]
Warrants assumptions	1.78
Measurement Input, Price Volatility [Member] | The 2019 Ladenburg Warrants [Member]
Warrants assumptions	1.86
Measurement Input, Expected Term [Member] | The 2019 Domestic Warrants [Member]
Warrants assumptions	4.57
Measurement Input, Expected Term [Member] | The 2019 Foreign Warrants [Member]
Warrants assumptions	4.57
Measurement Input, Expected Term [Member] | The 2019 Ladenburg Warrants [Member]
Warrants assumptions	4.05
Measurement Input, Risk Free Interest Rate [Member] | The 2019 Domestic Warrants [Member]
Warrants assumptions	0.0025
Measurement Input, Risk Free Interest Rate [Member] | The 2019 Foreign Warrants [Member]
Warrants assumptions	0.0027
Measurement Input, Risk Free Interest Rate [Member] | The 2019 Ladenburg Warrants [Member]
Warrants assumptions	0.0022
Measurement Input, Expected Dividend Rate [Member] | The 2019 Domestic Warrants [Member]
Warrants assumptions	0
Measurement Input, Expected Dividend Rate [Member] | The 2019 Foreign Warrants [Member]
Warrants assumptions	0
Measurement Input, Expected Dividend Rate [Member] | The 2019 Ladenburg Warrants [Member]
Warrants assumptions	0
Measurement Input, Share Price [Member] | The 2019 Domestic Warrants [Member]
Warrants assumptions	1.18
Measurement Input, Share Price [Member] | The 2019 Foreign Warrants [Member]
Warrants assumptions	1.54
Measurement Input, Share Price [Member] | The 2019 Ladenburg Warrants [Member]
Warrants assumptions	1.17

Note 12 - Stockholders' Equit_2

Note 12 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Oct. 27, 2020	May 13, 2020	Mar. 06, 2020	Mar. 31, 2020	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2015	Mar. 31, 2015	Sep. 30, 2011	Jan. 15, 2021	Aug. 13, 2019	May 31, 2019	Feb. 29, 2016	Oct. 31, 2015
Preferred Stock, Shares Authorized (in shares)					5,000,000	5,000,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)					0	0
Payments of Stock Issuance Costs							$ 200
Class of Warrant or Right, Issued During Period (in shares)					15,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 1.63	$ 1.63
Class of Warrant or Right, Outstanding (in shares)					7,082,000	7,067,000
Class of Warrant or Right, Exercised During Period (in shares)
Proceeds from Warrant Exercises							6,800		$ 201
China Kington [Member]
Payments of Stock Issuance Costs							200
Ladenburg Thalmann and Co. Inc. [Member]
Payments of Stock Issuance Costs										$ 300
Private Placement, Commission Percentage										6.00%
Payments of Stock Issuance Costs, Reimbursement of Expenses										$ 60
Payments of Stock Issuance Costs, Other										$ 300
The July 2011 Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)														139,520
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)														139,520
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)														$ 33.25			$ 0.2061	$ 1.81	$ 5
Class of Warrant or Right, Expired During Period (in shares)			35,107	35,107
Class of Warrant or Right, Outstanding (in shares)					0
March 2015 Short-term and Long-term Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)													649,133
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)													649,133
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																	0.2061	1.81	$ 5
Class of Warrant or Right, Expired During Period (in shares)									7,419
Class of Warrant or Right, Outstanding (in shares)					0
Class of Warrant or Right, Exercised During Period (in shares)									70,000
Proceeds from Warrant Exercises									$ 14
March 2015 Warrants [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)													$ 15
March 2015 Warrants [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)													$ 16.25
March 2015 Warrants Expiring March 6, 2020 [Member]
Class of Warrant or Right, Issued During Period (in shares)													278,200
March 2015 Warrants Expiring June 6, 2015 [Member]
Class of Warrant or Right, Issued During Period (in shares)													370,933
October 2015 Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)												442,802
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)												442,802
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 5					$ 0.2061	$ 1.81
Class of Warrant or Right, Expired During Period (in shares)	15,320					15,320
Class of Warrant or Right, Outstanding (in shares)					0	0
Class of Warrant or Right, Exercised During Period (in shares)						22,680
Proceeds from Warrant Exercises						$ 5
The June 2019 Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)											1,371,427
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											1,371,427
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)											$ 0.87
Class of Warrant or Right, Expired During Period (in shares)								571,428
Class of Warrant or Right, Outstanding (in shares)					0
Class of Warrant or Right, Exercised During Period (in shares)								571,428	228,571
Proceeds from Warrant Exercises								$ 497	$ 199
Class of Warrant or Right Call Feature Minimum Stock Price (in dollars per share)											$ 1
The June 2019 Warrants [Member] | China Kington [Member]
Payments for Commission, Exercise of Warrants								$ 29	$ 12
Exercise of Warrants, Commission, Percent				6.00%				6.00%	6.00%
The 2019 Domestic Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)										4,198,566
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)										4,198,566
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)										$ 1.15
Class of Warrant or Right, Outstanding (in shares)					0
Warrants and Rights Outstanding							$ 4,900			$ 3,100						$ 3,100
Payments of Stock Issuance Costs Allocated to Warrants										200
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs										$ 300
The 2019 Ladenburg Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)										167,942
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)										167,942
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 0.99			$ 1.25
Warrants and Rights Outstanding							$ 200									100
Payments of Stock Issuance Costs Allocated to Warrants										$ 59
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs										$ 65
The 2019 Foreign Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 0.99
Exercise of Warrants, Commission, Percent							6.00%
Warrants and Rights Outstanding							$ 4,200									$ 2,000
New Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							6,898,566
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 1.65
Warrants and Rights Outstanding, Term (Year)							5 years 182 days
TLF Bio Innovation 2021 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)															15,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)															$ 0.6718
Warrants and Rights Outstanding, Term (Year)															5 years
TLF Bio Innovation [Member]
Stock Issued During Period, Shares, New Issues (in shares)		1,000
Proceeds from Issuance of Common Stock		$ 1
ATM Program [Member]
Stock Issued During Period, Shares, New Issues (in shares)								5,836,792
Proceeds from Issuance of Common Stock								$ 5,600
Payments of Stock Issuance Costs								$ 400
Private Placement [Member]
Payments of Stock Issuance Costs											$ 27
Private Placement [Member] | Three Accredited Investors [Member]
Stock Issued During Period, Shares, New Issues (in shares)											1,371,427
Issuance of Stock and Warrants During the Period, Value											$ 2,400
Private Placement [Member] | Xiao Rui Liu [Member]
Issuance of Stock and Warrants During the Period, Value											1,000
Private Placement [Member] | Hai Dong Pang [Member]
Issuance of Stock and Warrants During the Period, Value											400
Private Placement [Member] | Ping Huang [Member]
Issuance of Stock and Warrants During the Period, Value											1,000
Private Placement [Member] | China Kington [Member]
Payments of Stock Issuance Costs											$ 100
Private Placement, Commission Percentage											6.00%
August 2019 Common Stock Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)										4,198,566
Payments of Stock Issuance Costs										$ 500
Proceeds from Issuance of Stock and Warrants										$ 4,200

Note 12 - Stockholders' Equit_3

Note 12 - Stockholders' Equity - Outstanding Warrants (Details) shares in Thousands	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Outstanding warrants (in shares) | shares	7,067
Outstanding warrants, weighted-average exercise price (in dollars per share) | $ / shares	$ 1.63
Warrants granted (in shares) | shares	15
Warrants granted, weighted average exercise price (in dollars per share) | $ / shares	$ 0.67
Warrants exercised (in shares) | shares
Warrants exercised, weighted average exercise price (in dollars per share) | $ / shares
Warrants expired (in shares) | shares
Warrants expired, weighted average exercise price (in dollars per share) | $ / shares
Outstanding warrants (in shares) | shares	7,082
Outstanding warrants, weighted-average exercise price (in dollars per share) | $ / shares	$ 1.63

Note 13 - Equity-based Compen_3

Note 13 - Equity-based Compensation (Details Textual) - USD ($) $ in Thousands	Jan. 15, 2021	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)		0	0
Proceeds from Stock Options Exercised		$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		55,000
Share-based Payment Arrangement, Expense		$ 183	$ 57
Share-based Payment Arrangement, Nonemployee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		0	0
Share-based Payment Arrangement, Expense		$ 30
Employees and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		55,000	20,000
Employee Stock Options and RSUs [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 900
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		2 years 226 days
Restricted Stock [Member]
Share-based Payment Arrangement, Expense		$ 130	$ 45
Restricted Stock [Member] | Share-based Payment Arrangement, Nonemployee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		0	0
Share-based Payment Arrangement, Expense		$ 53	$ 12
Restricted Stock [Member] | Employees and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		0	0
The 2007 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		10 years
The 2017 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)		2,318,486
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock		4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	1,671,303
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)		3,646,727
The 2017 Omnibus Incentive Plan [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum		10.00%
The 2017 Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		4 years
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		10 years
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member] | Shareholder of More Than 10% [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		5 years
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent		100.00%
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member] | Incentive Stock Options (ISOs) [Member] | Shareholder of More Than 10% [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent		110.00%

Note 13 - Equity-based Compen_4

Note 13 - Equity-based Compensation - Stock Options Outstanding (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Outstanding awards (in shares)	3,165,000
Outstanding, weighted-average exercise price (in dollars per share)	$ 2.05
Outstanding, weighted-average remaining contractual life (Year)	7 years 146 days		7 years 219 days
Outstanding, aggregate intrinsic value	$ 309		$ 189
Options granted (in shares)	55,000
Options granted, weighted-average exercise price (in dollars per share)	$ 1.09
Options exercised (in shares)	0	0
Options exercised, weighted-average exercise price (in dollars per share)
Options forfeited/cancelled (in shares)	(82,000)
Options forfeited/cancelled, weighted-average exercise price (in dollars per share)	$ 3.97
Outstanding awards (in shares)	3,138,000		3,165,000
Outstanding, weighted-average exercise price (in dollars per share)	$ 1.98		$ 2.05
Vested and expected to vest (in shares)	2,797,000
Vested and expected to vest, weighted-average exercise price (in dollars per share)	$ 2.12
Vested and expected to vest, weighted-average remaining contractual life (Year)	7 years 73 days
Vested and expected to vest, aggregate intrinsic value	$ 254
Vested (in shares)	1,459,000
Vested, weighted-average exercise price (in dollars per share)	$ 3.21
Vested, weighted-average remaining contractual life (Year)	5 years 109 days
Vested, aggregate intrinsic value	$ 64
Exercisable (in shares)	1,459,000
Exercisable, weighted-average exercise price (in dollars per share)	$ 3.21
Exercisable, weighted-average remaining contractual life (Year)	5 years 109 days
Exercisable, aggregate intrinsic value	$ 64
Restricted Stock Units (RSUs) [Member]
Restricted stock units granted (in shares)
Restricted stock units vested (in shares)
Restricted stock units vested, weighted-average exercise price (in dollars per share)
Restricted stock units cancelled (in shares)

Note 13 - Equity-based Compen_5

Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) - Employees and Directors [Member] - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Expected price volatility	164.44%	143.83%
Expected term (Year)	6 years 69 days	6 years 167 days
Risk-free interest rate	1.09%	0.99%
Dividend yield	0.00%	0.00%
Weighted-average fair value of options granted during the period (in dollars per share)	$ 1.04	$ 0.53

Note 13 - Equity-based Compen_6

Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Stock-based compensation expense	$ 183	$ 57
Research and Development Expense [Member]
Stock-based compensation expense	4	7
Selling and Marketing Expense [Member]
Stock-based compensation expense	31	9
General and Administrative Expense [Member]
Stock-based compensation expense	$ 148	$ 41

Note 14 - License, Collaborat_3

Note 14 - License, Collaboration and Distribution Agreements (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Revenue from Contract with Customer, Including Assessed Tax	$ 1,807	$ 1,892
Avenova Product [Member]
Revenue from Contract with Customer, Including Assessed Tax	1,575	1,539
Avenova Direct [Member]
Revenue from Contract with Customer, Including Assessed Tax	1,200	800
McKesson Corporation [Member] | Avenova Product [Member]
Contract with Customer, Liability, Revenue Recognized	100	$ 600
McKesson Corporation [Member] | Avenova Product [Member] | Accounts Payable and Accrued Liabilities [Member]
Contract with Customer, Liability, Total	900		$ 700
McKesson Corporation [Member] | Avenova Product [Member] | Prepaid Expenses and Other Current Assets [Member]
Contract with Customer, Rebate Liability, Current	$ 68		$ 100

Note 14 - License, Collaborat_4

Note 14 - License, Collaboration and Distribution Agreements - Changes in Assets and Liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Contract Liabilities: Deferred Revenue, Balance at beginning of the period	$ 2
Contract Liabilities: Deferred Revenue, additions	1
Contract Liabilities: Deferred Revenue, deductions	(2)
Contract Liabilities: Deferred Revenue, Balance at the end of the period	1
Contract Liabilities: Accrued Liabilities,Balance at beginning of the period	573
Contract Liabilities: Accrued Liabilities, additions	573
Contract Liabilities: Accrued Liabilities, deductions	(352)
Contract Liabilities: Accrued Liabilities, Balance at the end of the period	794
Contract Liabilities, Balance at beginning of the period	575
Contract Liabilities, additions	574
Contract Liabilities, deductions	(354)
Contract Liabilities, Balance at the end of the period	$ 795

Note 14 - License, Collaborat_5

Note 14 - License, Collaboration and Distribution Agreements - Total Revenues (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Total sales, net	$ 1,807	$ 1,892
Transferred over Time [Member]
Total sales, net	575	434
Transferred at Point in Time [Member]
Total sales, net	$ 1,232	$ 1,458

Note 15 - Employee Benefit Pl_2

Note 15 - Employee Benefit Plan (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
The 401(k) Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0

Note 16 - Related Party Trans_3

Note 16 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands	Nov. 17, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Accounts Receivable, Related Parties		$ 100		$ 200
Accounts Payable, Related Parties		$ 10		$ 8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		55,000
Share-based Payment Arrangement, Expense		$ 183	$ 57
Share-based Payment Arrangement, Nonemployee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		0	0
Share-based Payment Arrangement, Expense		$ 30
Partner and Senior Vice President of China Kington [Member] | Share-based Payment Arrangement, Nonemployee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	300,000
Partner and Senior Vice President of China Kington [Member] | Share-based Payment Arrangement, Nonemployee [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	1 year

Note 16 - Related Party Trans_4

Note 16 - Related Party Transactions - Related Party Revenue, Cost of Goods Sold, and Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Total related party revenue		$ 173
Cost of goods sold		90
Total related party expenses		62
Director Bob Wu [Member]
Total related party expenses		50
China Kington [Member]
Total related party expenses		12
China Kington [Member] | Broker Fee for the Exercise of the June 2019 Warrants [Member]
Total related party expenses		12
NeutroPhase [Member]
Total related party revenue		173
Cost of goods sold		$ 90

Note 17 - Paycheck Protection_2

Note 17 - Paycheck Protection Program (Details Textual) $ in Millions	May 06, 2020USD ($)
Paycheck Protection Program CARES Act [Member] | Wells Fargo Bank [Member]
Proceeds from Issuance of Long-term Debt, Total	$ 0.9